Harwood Feffer LLP Announces Investigation of Trinity Biotech plc
May 22, 2017
NEW YORK, May 22, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against officers and directors of Trinity Biotech plc ("Trinity" or the "Company") (NASDAQ: TRIB).
On October 4, 2016, Trinity disclosed that that U.S. Food and Drug Administration ("FDA") had recommended that the Company withdraw its premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care-Analyzer. Trinity further announced that based on the FDA's recommendation the Company would withdraw the submission, close one of its facilities and take a noncash write-off of over $50 million.
On this news, Trinity's American Depositary Shares ("ADSs") lost nearly 50% of their value, and have not recovered.
Our investigation concerns whether the Company and its officers and directors omitted to disclose material information and/or issued misleading disclosures in connection with the foregoing.
If you own Trinity American Depositary Shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP